On The Horizon: New Oral Therapies for Type 2 Diabetes Mellitus
Journal Title: International Journal of Diabetology & Vascular Disease Research (IJDVR) - Year 2013, Vol 1, Issue 3
Abstract
The first documented case of diabetes mellitus occurred earlier than 4000 BC. Since then, many of the brightest minds in medicine have dedicated their time and effort toward developing treatments that can reverse the course of this deadly disease. As our understanding of the pathogenesis of diabetes increases, so does the availability of treatment options. The fight against diabetes once only had metformin and sulfonylureas as the cornerstone of oral treatment, but now, multiple classes have been added to this armamentarium including thiazolidenediones (TZDs) and dipeptidyl peptidase IV (DDP IV) inhibitors. These therapies provide reasonable durable glycemic control but are unable to arrest the natural progression of diabetes or the eventual need for insulin. By utilizing our growing knowledge on the pathogenesis of diabetes, a number of new therapeutic agents are in development to overcome the shortcomings of current therapies. Promising options on the horizon include sodium-coupled glucose cotransport 2 (SGLT2) inhibitors, Ranolazine, Salicylates, second generation Peroxisome proliferator ac-tivator receptor agonists (PPARs), and 11-beta hydroxysteroid dehydrogenase type 1 inhibitors (11-beta HSD1 inhibitors). Various molecules, including some enzymes, are also in development particularly to address beta cell preservation and its sensitivity to glucose, while minimizing hypoglycemia. Most of these new classes of drugs consist of daily administration, simplifying the regimen for patients and likely increasing medication compliance. This article reviews the new agents that are advancing through clinical trials, their mechanism of actions, glucose lowering effect and possible side effects and limitations
Authors and Affiliations
Intekhab Ahmed
Keywords
Related Articles
- EP ID EP197782
- DOI 10.19070/2328-353X-130004
- Views 152
- Downloads 0
Application of Premixed Insulin NovoMix®30 and NovoRapid® as Multiple Daily Injections or as Basal Bolus Format in Selected Diabetic Patients: Practical Evidence from Prospective Case Series
Application of Premixed Insulin NovoMix®30 and NovoRapid® as Multiple Daily Injections or as Basal Bolus Format in Selected Diabetic Patients: Practical Evidence from Prospective Case Series
Effect of Oral Infections on Serum Creatinine Levels in Diabetic Rats
Aim: The aim of this study was to evaluate the relationship between pulpal and/or periodontal disease and serum creatinine levels in a rat model of diabetes mellitus. Methods: Eighty male rats (Rattus norvegicus albinus,...
The Attitudes about Complex Therapy Scale (ACTS) in Type 2 Diabetes and Cardiovascular Disease: Development, Validity and Reliability
Background: Type 2 diabetes is associated with cardiovascular disease, and patients with both conditions are prescribed complex medication regimens. Aim: The aim was to develop a reliable and valid measure of attitudes a...
Nature as an Ideal Rhythm Model for Optimal Cardiovascular Physiology and Health
This article innovatively describes nature as an ultimate rhythm model for optimizing human physiology and health. Circadian rhythms of biological systems orchestrate cell metabolism and survivorship for reasonable longe...
Estimating the Lag Between Onset and Diagnosis of Diabetes from the Prevalence of Diabetic Retinopathy Among Indian Population
Background & Objectives: Type 2 Diabetes Mellitus (T2DM) is often characterized by an asymptomatic phase of around 4-7 years between the onset of diabetes and its clinical diagnosis. Diabetic retinopathy is the one to b...